Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis.

ABSTRACT:

Importance

Older adults with atopic dermatitis (AD) face unique treatment challenges, including comorbidities, polypharmacy, and a higher risk for infections (eg, herpes zoster). Furthermore, limited data are available from clinical trials for treatments in this population. In phase 3 studies, tralokinumab showed superior efficacy in moderate-to-severe AD vs placebo, but results were not stratified by age group.

Objective

To evaluate the safety and efficacy of tralokinumab in older (≥65 years) patients with moderate-to-severe AD.

Design, setting, and participants

A post hoc analysis for adults 65 years or older was conducted from a subset of patients in the US, Canada, Europe, and Asia in 3 randomized, placebo-controlled, phase 3 trials (ECZTRA 1 and 2 [monotherapy] a

SUBMITTER: Merola JF 

PROVIDER: S-EPMC10448370 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature